文献速递膀胱癌与上尿路尿路上皮癌

原发性膀胱肿瘤整块切除与常规电切的比较(eBLOC):一项前瞻性、多中心、开放标签、3期随机对照试验

En Bloc Versus Conventional Resection of Primary Bladder Tumor (eBLOC): A Prospective, Multicenter, Open-label, Phase 3 Randomized Controlled Trial.
PubMed 文献 · Eur Urol Oncol · 2023-08-04

eBLOC研究将384例临床非肌层浸润性膀胱癌(NMIBC,肿瘤1–3 cm、不超过3个)患者按1:1随机分入整块经尿道膀胱肿瘤电切(eTURB)组(192例)或常规电切(cTURB)组(192例)。结果显示eTURB标本中逼尿肌检出率高于cTURB(80.7% vs 71.1%,混合模型P=0.01),膀胱穿孔和闭孔反射更少,手术时间无差异;中位随访13个月时两组膀胱癌复发无显著差异。

要点

  • eTURB标本逼尿肌检出率80.7% vs cTURB 71.1%(混合模型P=0.01)。
  • 膀胱穿孔5.6% vs 12%(差值-6.4%,95%CI -12.2%至-0.6%),eTURB更少。
  • 中位随访13个月复发18.4% vs 16.7%(HR 0.87,95%CI 0.49–1.52;P=0.6),无显著差异。

核心结论

  • 在肿瘤1–3 cm、不超过3个的临床NMIBC患者中,eTURB取到的病理标本中逼尿肌比例高于cTURB。
  • eTURB的闭孔反射和膀胱穿孔发生率低于cTURB,手术时间两者无差异。
  • eTURB改善了NMIBC的质量指标,但其长期肿瘤学获益差异仍不确定。

研究设计与样本

  • 前瞻性、多中心、开放标签、3期随机对照试验(eBLOC),2019年1月至2022年1月入组。
  • 纳入临床cTa–T1 NMIBC、肿瘤1–3 cm且不超过3个的患者,按1:1随机分为eTURB组192例与cTURB组192例,共384例。
  • 共切除452个肿瘤用于主要结局分析;试验在ClinicalTrials.gov注册号为NCT03718754。

主要发现

  • 主要结局逼尿肌检出率:eTURB组80.7% vs cTURB组71.1%(混合模型P=0.01)。
  • 膀胱穿孔:eTURB组5.6% vs cTURB组12%(差值-6.4%,95%CI -12.2%至-0.6%)。
  • 闭孔反射:eTURB组8.4% vs cTURB组16%(差值-7.6%,95%CI -14.3%至-0.9%)。
  • 手术时间:eTURB组26分钟(IQR 20–38)vs cTURB组25分钟(IQR 17–35),差值1分钟(95%CI -25.9至4.99)。
  • 二次电切:eTURB组24例、cTURB组34例,残留乳头状病变(pTa/pT1)56% vs 55.9%(差值0.1%,95%CI -25.5%至25.7%);中位随访13个月(IQR 7–20)复发18.4% vs 16.7%(Cox HR 0.87,95%CI 0.49–1.52;P=0.6)。

关键数值与推荐

  • 随机分组为1:1,eTURB组n=192、cTURB组n=192,共384例;纳入标准为临床cTa–T1 NMIBC、肿瘤1–3 cm、不超过3个。
  • 主要结局为标本中逼尿肌检出率;次要结局包括膀胱穿孔、二次电切残留病变、侧切缘阳性、深切缘阳性、手术时间、闭孔反射、eTURB转cTURB、无复发生存及3个月复发。

临床怎么用

  • 原文结论为eTURB较cTURB提高了病理标本中逼尿肌检出率,并降低闭孔反射和膀胱穿孔发生率。
  • 原文指出eTURB改善了NMIBC的质量指标,但其长期肿瘤学获益差异仍不确定。

局限性

  • 原文结论指出eTURB的长期肿瘤学获益差异仍不确定。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: En bloc transurethral resection of the bladder (eTURB) might improve the surgical management of non-muscle-invasive bladder cancer (NMIBC) in comparison to conventional TURB (cTURB). OBJECTIVE: To evaluate whether eTURB is superior to cTURB in resection of NMIBC and specimen retrieval. DESIGN, SETTING, AND PARTICIPANTS: This was a randomized, multicenter trial in patients with up to three cTa-T1 NMIBC tumors of 1-3 cm in size, who were enrolled from January 2019 to January 2022. INTERVENTION: Participants were randomized 1:1 to undergo eTURB (n = 192) or cTURB (n = 192). OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: The primary outcome was the prevalence of detrusor muscle (DM) in the specimen retrieved. Secondary endpoints included bladder perforation, persistent disease at second-look TURB, positive lateral resection margin, positive deep resection margin, operation time, perforation rate, obturator reflex, conversion from eTURB to cTURB, recurrence-free survival, and disease recurrence at 3 mo. RESULTS AND LIMITATIONS: A total of 384 patients were randomized to undergo eTURB or cTURB. A total of 452 tumors were resected and analyzed for the primary outcome. eTURB was superior to cTURB in retrieval of DM (80.7% vs 71.1%; mixed-model p = 0.01). Bladder perforation (5.6% vs 12%; difference -6.4%; 95% confidence interval [CI] -12.2% to -0.6%) and obturator reflex (8.4% vs 16%; difference -7.6%; 95% CI -14.3% to -0.9%) were less frequent in the eTURB arm than in the cTURB arm. Operation time did not differ between the two techniques (26 min, interquartile range [IQR] 20-38 for eTURB vs 25 min, IQR 17-35 for cTURB; difference 1 min, 95% CI -25.9 to 4.99). Second-look TURB was performed in 24 patients in the eTURB arm and 34 in the cTURB arm, with no difference in the rate of residual papillary disease (pTa/pT1: 56% vs 55.9%; difference 0.1%, 95% CI -25.5% to 25.7%). At median follow-up of 13 mo (IQR 7-20), 18.4% of the patients in the eTURB arm and 16.7% in the cTURB arm had experienced bladder cancer recurrence (Cox hazard ratio 0.87, 95% CI 0.49-1.52; p = 0.6). CONCLUSIONS: In patients with clinical NMIBC with up to three tumors of 1-3 cm in size, tumor removal via eTURB resulted in a higher rate of DM in the pathologic specimen in comparison to cTURB. Moreover, eTURB was associated with lower frequency of obturator reflex and bladder perforation than cTURB was. While improving on the quality indicators for NMIBC, the long-term differential oncologic benefits of eTURB remain uncertain. PATIENT SUMMARY: We compared two techniques for removal of bladder tumors and found that tumor removal in a single piece, called en bloc resection, provides a better-quality specimen for pathology analysis and fewer complications in comparison to the conventional method. This trial is registered at ClinicalTrials.gov as NCT03718754.

来源:Eur Urol Oncol,查看原文。版权归原作者所有。

引用

  1. D'Andrea D, Soria F, Hurle R, et al. En Bloc Versus Conventional Resection of Primary Bladder Tumor (eBLOC): A Prospective, Multicenter, Open-label, Phase 3 Randomized Controlled Trial. Eur Urol Oncol. 2023. PMID: 37543464. doi:10.1016/j.euo.2023.07.010

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。